Detalles de la búsqueda
1.
First-line single-agent pembrolizumab for PD-L1-positive (tumor proportion score ≥ 50%) advanced non-small cell lung cancer in the real world: impact in brain metastasis: a national French multicentric cohort (ESCKEYP GFPC study).
Cancer Immunol Immunother
; 72(1): 91-99, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35729418
2.
First-line pembrolizumab with or without platinum doublet chemotherapy in non-small-cell lung cancer patients with PD-L1 expression ≥50.
Future Oncol
; 17(23): 3007-3016, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-34156285
3.
Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol
; 21(9): 1224-1233, 2020 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-32888454
4.
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials.
Expert Rev Anticancer Ther
; : 1-6, 2024 Jun 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38813930
5.
Characterization of Patients with EGFR Mutation-Positive NSCLC Following Emergence of the Osimertinib Resistance Mutations, L718Q or G724S: A Multicenter Retrospective Observational Study in France.
Onco Targets Ther
; 17: 439-448, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38836187
6.
Profiles, diagnostic process, and patterns of care of patients with stage III non-small cell lung cancer: A French national study.
Respir Med Res
; 85: 101087, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38657298
7.
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Ther Adv Med Oncol
; 16: 17588359241236451, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38455711
8.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
J Cancer Res Clin Oncol
; 149(16): 15095-15102, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37626173
9.
Predictors of three-month mortality and severe chemotherapy-related adverse events in patients aged 70 years and older with metastatic non-small-cell lung cancer: A secondary analysis of ESOGIA-GFPC-GECP 08-02 study.
J Geriatr Oncol
; : 101506, 2023 May 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37211514
10.
Three-Year Overall Survival of Patients With Advanced Non-Small-Cell Lung Cancers With ≥50% PD-L1 Expression Treated With First-Line Pembrolizumab Monotherapy in a Real-World Setting (ESCKEYP GFPC Study).
J Immunother
; 2023 Oct 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37807621
11.
Cost effectivenes of erlotinib versus chemotherapy for first-line treatment of non small cell lung cancer (NSCLC) in fit elderly patients participating in a prospective phase 2 study (GFPC 0504).
BMC Cancer
; 12: 301, 2012 Jul 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-22817667
12.
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study.
Cancers (Basel)
; 14(7)2022 Mar 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-35406523
13.
Lung cancer trends and tumor characteristic changes over 20 years (2000-2020): Results of three French consecutive nationwide prospective cohorts' studies.
Lancet Reg Health Eur
; 22: 100492, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36108315
14.
Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).
Lung Cancer
; 161: 122-127, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583220
15.
Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus "at progression" cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis.
Ther Adv Med Oncol
; 13: 17588359211006983, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33948123
16.
Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.
Lung Cancer
; 157: 40-47, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980420
17.
Impact of Programmed Death Ligand 1 Expression in Advanced Non-Small-Cell Lung Cancer Patients, Treated by Chemotherapy (GFPC 06-2015 Study).
Onco Targets Ther
; 13: 13299-13305, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408480
18.
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019.
Cancers (Basel)
; 12(12)2020 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33276639
19.
Encephalitis related to immunotherapy for lung cancer: Analysis of a multicenter cohort.
Lung Cancer
; 143: 36-39, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32200139
20.
Efficacy and safety of programmed cell-death-protein-1 and its ligand inhibitors in pretreated patients with epidermal growth-factor receptor-mutated or anaplastic lymphoma kinase-translocated lung adenocarcinoma.
Medicine (Baltimore)
; 99(3): e18726, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32011450